美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Militia Long/Short Equity ETF

27.49

+0.00720.03%

成交量：2.66萬

成交額：72.74萬

市值：- -

市盈率：- -

高：27.49

開：27.40

低：27.25

收：27.48

資料載入中...

總覽公司新聞公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞

中國目前唯一獲批肝癌一線雙免疫聯合療法出現，全新患者援助計劃啓動

艾伯維“狙擊”普方生物：專利戰下政策如何助力行業規範？

21世纪经济报道

KRAS G12D先驅都扛不住了

消息：特朗普政府要求移民局追蹤並驅逐無陪伴兒童移民

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ORR"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":27.4872,"timestamp":1746043200000,"preClose":27.48,"halted":0,"volume":26641,"delay":0,"floatShares":2350000,"shares":0,"eps":0,"marketStatus":"盤後交易","change":0.0072,"latestTime":"04-30 16:35:47 EDT","open":27.4,"high":27.4872,"low":27.25,"amount":727433.745,"amplitude":0.008632,"askPrice":28.5,"askSize":15,"bidPrice":27.01,"bidSize":18,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1746057600000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":27.48,"sharesOutstanding":2350000,"nav":27.61,"aum":64883500,"bidAskSpread":0,"volumeRatio":0.432988},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":2350000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.432988,"shares":0,"dividePrice":0,"high":27.4872,"amplitude":0.008632,"preClose":27.48,"low":27.25,"week52Low":25.63,"pbRate":"--","week52High":28.69,"institutionHeld":0,"latestPrice":27.4872,"committee":0.090909,"eps":0,"divideRate":0,"volume":26641,"delay":0,"ttmEps":0,"open":27.4,"prevYearClose":25.88,"prevWeekClose":27.8493,"prevMonthClose":27.84,"prevQuarterClose":27.84,"fiveDayClose":28.129,"twentyDayClose":27.92,"sixtyDayClose":26.9028},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ORR\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2524890141","title":"中國目前唯一獲批肝癌一線雙免疫聯合療法出現，全新患者援助計劃啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=2524890141","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524890141?lang=zh_tw&edition=fundamental","pubTime":"2025-04-01 09:35","pubTimestamp":1743471328,"startTime":"0","endTime":"0","summary":"近日，两款肿瘤免疫治疗药物——欧狄沃（纳武利尤单抗注射液）与逸沃（伊匹木单抗注射液）的联合疗法获得中国国家药品监督管理局批准新增适应症，适用于不可切除或晚期肝细胞癌成人患者的一线治疗，成为中国首个且目前唯一获批的肝细胞癌一线双免疫联合疗法。“肝癌在中国的疾病负担尤为沉重，发病人数位居全球第一，每年导致的癌症死亡人数也高居所有癌症第二。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504013361966091.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ORR","BK4097","OS"],"gpt_icon":0},{"id":"2522020873","title":"艾伯維“狙擊”普方生物：專利戰下 政策如何助力行業規範？","url":"https://stock-news.laohu8.com/highlight/detail?id=2522020873","media":"21世纪经济报道","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522020873?lang=zh_tw&edition=fundamental","pubTime":"2025-03-25 18:28","pubTimestamp":1742898487,"startTime":"0","endTime":"0","summary":"继起诉百济神州之后，艾伯维将矛头指向普方生物 。Genmab方面坚决否认上述指控，“艾伯维并未应用该技术开发任何产品，这只是艾伯维近期针对竞争对手提起的多起诉讼中的一起，这些诉讼都是指控艾伯维前员工盗用了其商业机密。”此次艾伯维未对被告方主张或行使任何专利权，而是寻求损害赔偿和广泛的禁令救济。Genmab称将针对艾伯维的诉求积极为公司辩护。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250325201336a6a3670d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250325201336a6a3670d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1267930490.SGD","LU1983299246.USD","LU0256863811.USD","LU0198837287.USD","LU2092937221.SGD","LU1267930573.SGD","IE0002141913.USD","OC","LU1291159041.SGD","LU2468319806.SGD","LU2347655156.SGD","LU0965509283.SGD","LU1929549753.HKD","LU2237443549.SGD","LU2129689431.USD","LU1496350502.SGD","LU0868494617.USD","LU0985320562.USD","BK4588","LU1551013425.SGD","LU1732799900.SGD","LU0861579265.USD","LU0912757837.SGD","LU0310799852.SGD","LU1718418525.SGD","LU2106854487.HKD","LU2112291526.USD","BK4139","OS","LU1989772840.SGD","IE0002270589.USD","IE00BVYPNW00.USD","LU1989772923.USD","LU0234570918.USD","LU1989771016.USD","LU2237443465.HKD","LU0320765646.SGD","LU0256863902.USD","BK4086","ORR","LU0553294199.USD","LU0795875169.SGD","LU2129689605.HKD","LU1003077747.HKD","SG9999001440.SGD","LU1496350171.SGD","BK4550","LU0417517546.SGD","SG9999015952.SGD","ABBV"],"gpt_icon":0},{"id":"2518213795","title":"KRAS G12D先驅都扛不住了","url":"https://stock-news.laohu8.com/highlight/detail?id=2518213795","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518213795?lang=zh_tw&edition=fundamental","pubTime":"2025-03-10 16:17","pubTimestamp":1741594679,"startTime":"0","endTime":"0","summary":"热度持续攀升的KRAS G12D领域，却不断传出糟糕的消息。3月5日，据外媒消息，BMS已经放弃开发KRAS G12D抑制剂MRTX1133，原因是前景堪忧。这并非KRAS G12D赛道的第一个坏消息。如今，随着又一位重磅选手折戟，无疑给KRAS G12D领域敲响了警钟，尤其是对于处在跟随阶段的国内药企来说。很显然，这些国内跟随的选手需要进一步审视其KRAS G12D分子的结构。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/252604","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["ORR"],"gpt_icon":0},{"id":"2513531717","title":"消息：特朗普政府要求移民局追蹤並驅逐無陪伴兒童移民","url":"https://stock-news.laohu8.com/highlight/detail?id=2513531717","media":"联合早报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513531717?lang=zh_tw&edition=fundamental","pubTime":"2025-02-23 22:39","pubTimestamp":1740321574,"startTime":"0","endTime":"0","summary":"美国移民和海关执法局（ICE）的内部备忘录显示，特朗普政府计划扩大针对无陪伴移民儿童的驱逐行动，并要求ICE特工追踪数十万名未成年非法入境者，这些儿童未随父母或合法监护人入境。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"zaobao_highlight","url":"https://www.zaobao.com/realtime/world/story20250223-5920076","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zaobao.com/realtime/world/story20250223-5920076","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zaobao_highlight","symbols":["DNA","HHS","ORR","BK4139","BK4109","BK4009"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{}}}